Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
Children's Hospital of Philadelphia
Boston Children's Hospital
Taiho Oncology, Inc.
Massachusetts General Hospital
Ossium Health, Inc.
Institute of Hematology & Blood Diseases Hospital, China
Cullgen (Shanghai),Inc
Medical University of Gdansk
Ohio State University Comprehensive Cancer Center
Peter MacCallum Cancer Centre, Australia
Children's Hospital of Philadelphia
UNC Lineberger Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Affiliated Hospital of Qinghai University
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
City of Hope Medical Center
Medical College of Wisconsin
National Institutes of Health Clinical Center (CC)
Sanguine Biosciences
Tampere University Hospital
Sanguine Biosciences
European Institute of Oncology
Universitaire Ziekenhuizen KU Leuven
Hospital Universitari Vall d'Hebron Research Institute
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
University of Nebraska
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
University of Alabama at Birmingham
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Baylor College of Medicine
Malaghan Institute of Medical Research
Brown University
Rutgers, The State University of New Jersey
Roswell Park Cancer Institute
University of California, San Francisco
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
PrECOG, LLC.
CTI BioPharma
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center